While momenta can produce biosimilars. The markets for them keep getting smaller due to new drug introductions by a number of competitors. Their novel drug business is at best suspect. This company has always been a show me- but they can not , kind of company.JMHO
No news when Novartis reported earnings( glatopa ) looks like sales very small. The payment from Mylan will not show up till next qtr. And it seams mkt is discounting it already. With all the talk about high drug prices would of expected this as a generic co to hold a little better. Looking for some catalyst to move it higher but do not see any thing on the horizon till late 2017, 2018 if they can deliver.
There has never been a transparent news release until during the earnings release that there was an unplanned outage, Just do not trust management to be forthcoming untill after the fact , which is my reasoning to stay away from a big position in this company. Commodity cycle winding down.
Still think they have unplanned outages that hurt results this coming quarter. along with week prices of Fertilizers.
These guys could have more unreported down time. People , OK I do not trust management to be forthcoming with information. So not adding to any positions. Waiting on earnings.
Sorry for spelling error.
Momenta Pharmaceuticals, Inc. MNTA announced that its partner Sandoz (a Novartis NVS Company) has initiated the launch of once-daily Glatopa, the first generic version of Teva Pharmaceuticals’ TEVA daily Copaxone (20mg) in the U.S.
Listened to Momenta (JP Morgan presentation today) they talked how hard it has been for their generic to gain traction. Teva doing good job against competition. My 2 c worth
Some good info, nothing earth shattering. Possibilities with medium probabilities. Talked alot about 2019 and product intros then, not now. Copaxone 3 time weekly substitute, Humira, Orencia subs. Portfolio of products not one hit wonders.Competition will water down results.Their novel drug programs in two years might- repeat might- be a star for someone to want to own( no significant results now).
CFO states lousy 4th qtr due to inventory burn-off.. The first qtr will not be as bad as the normal 25% revenue decline due to lousy 4th qtr numbers. Talked about storage solutions revenue coming in the back half of 2016. Looks like an easy six months to accumulate IF you believe their numbers. Found it sad that they did not talk about their ongoing system service buis. Other than that it was a copy of the investors day cost reduction presentation.
3 to 6 months ago just started Glutopa sales, no agreement with Mylan, progress on Baxalta Humira copy, not much going for it. And thats if nothing comes from Necuparanib. or IvIG, or the real pie in the sky any thing from the Enoxoparin suit-never expect anything on this myself.